Market Overview

Roth Capital Upgrades ANI Pharmaceuticals To Buy On Valuation

Related ANIP
28 Biggest Movers From Friday
Wall Street's M&A Chatter From October 13-15: T-Mobile-Sprint, Radius Health, ANI Pharmaceuticals
U.S. opioid prescriptions down 12% last year, largest drop in 25 years (Seeking Alpha)
Related MRK
Stock Market Seems Directionless, Volatility Low As Investors Await News
Benzinga's Top Analyst Calls From April 18, 2018
Gillespie Robinson & Grimm Inc Buys Goldman Sachs Group Inc, Anadarko Petroleum Corp, SPDR ... (GuruFocus)
  • On Monday, Roth Capital upgraded shares of ANI Pharmaceuticals Inc (NASDAQ: ANIP) from Neutral to Buy.
  • After last week’s ~25 percent decline in the stock price, the experts find the valuation compelling once again.
  • Shares of ANI Pharmaceuticals continue to fall on Monday trading.

In a report issued Monday, analyst Scott R. Henry shares a few reasons to revalue the shares, for which he now has a $60.00 price target, which implies an upside of almost 50 percent. Among them, investors can count the further pipeline expansion coming from corticotropin, market share gains for EEMT, and a “stabilization of current negative sentiment.”

In the analyst’s opinion, the current valuation does not appropriately reflect ANI’s “sound fundamentals.” While some risks associated with the EEMT franchise remain, the firm thinks the risk profile is acceptable at current stock prices -- below $50 a share.

Let’s get back to the reasons for the upgrade.

1)   The anti-drug pricing sentiment triggered by Hillary Clinton’s remarks drove the stock price down, creating a buying opportunity for long-term investors.

1)   ANI paid Merck & Co., Inc. (NYSE: MRK) roughly $75 million for “an approved NDA for corticoptropin (similar to Acthar Gel from Mallinckrodt - for the treatment of multiple sclerosis, rheumatic disorders, dermatologic diseases, and other ailments).” The firm estimates that the compound has a yearly revenue potential of ~$200 million. Management targets to launch it in the second half of 2017. “Key assumptions include a ~$1 billion market, ~25% share, and a ~25% discount to the brand. This pipeline compound creates significant upside tail outcomes for ANIP shareholders,” the report assures.

2)   The EEMT franchise is strengthening.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Latest Ratings for ANIP

Feb 2018Canaccord GenuityMaintainsBuyBuy
Oct 2017Canaccord GenuityMaintainsBuy
Jul 2017Canaccord GenuityInitiates Coverage OnBuy

View More Analyst Ratings for ANIP
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Small Cap Analysis Price Target Reiteration Analyst Ratings


Related Articles (MRK + ANIP)

View Comments and Join the Discussion!